Dexcom One+ / Dexcom G7 Glucose Sensor
In recent years, continuous glucose monitoring has become one of the most important developments in the management of diabetes and metabolic disorders. The transition from point measurements obtained through finger-stick testing to systems that track glucose continuously has fundamentally changed how glycemic variability is understood. Along with this evolution, CGM manufacturers have had to adapt their technology not only from a medical perspective, but also in economic, logistical, and regulatory terms.
Dexcom, one of the global leaders in continuous glucose monitoring, has adopted a differentiated product-launch strategy depending on the specific characteristics of each country. As a result, Dexcom ONE+ is available in Romania, while in many Western European countries Dexcom G7—considered the company’s flagship system—is available. This difference frequently raises questions and, at times, concerns regarding the quality or technological level of the device offered locally.
It is essential to clarify from the outset that this situation does not reflect an inferiority of the Romanian market, nor does it mean that users in Romania receive a “lower-grade” technology. The difference between Dexcom ONE+ and Dexcom G7 is the result of a complex strategic decision, shaped by how effectively a technology can be used within a given healthcare system.
A key point that must be clearly understood is that Dexcom ONE+ and Dexcom G7 are built on the same core technological platform. The measurement principle is identical, as is the fundamental accuracy of interstitial glucose detection. These are not two different generations of sensors, but rather two configurations of the same technology, differentiated at the level of software functionality and ecosystem integration.
Romania is considered an emerging CGM market. Reimbursement options are limited, costs are largely borne by users, and the use of insulin pumps and automated insulin delivery systems remains relatively low. In such a context, introducing a fully featured system like Dexcom G7 directly would mean higher costs, advanced features that cannot be fully utilized, and reduced accessibility for the majority of users.
Dexcom ONE+ represents a deliberate adaptation to this local reality. It provides true continuous glucose monitoring, displaying values, trends, and essential alerts, while preserving the technological foundation of the G7 platform in a simpler and more sustainable form. This choice is not a limitation, but rather a step in building the CGM market and supporting metabolic education.
In Western European countries, the situation is different. CGM is often reimbursed, infrastructure for insulin pump integration is well developed, and demand for advanced features is high. In this context, Dexcom G7 can reach its full potential as part of a complex metabolic management ecosystem.
The difference between the two systems should therefore not be viewed as a hierarchy of quality, but as a difference in complexity level, adapted to the local healthcare environment. Dexcom ONE+ is not a step backward, but a necessary step toward making continuous glucose monitoring accessible and meaningful on a broader scale.
Dexcom ONE+ Explained as a CGM System: How It Works and What Should Be Properly Understood
Dexcom ONE+ is a continuous glucose monitoring system built on the Dexcom G7 technological platform, but configured for simpler and more accessible use. From a measurement perspective, Dexcom ONE+ operates in the same way as other modern CGM systems: it measures glucose concentration in the interstitial fluid and provides a continuous view of glycemic evolution, rather than a single isolated value.
The system features an all-in-one design, meaning that the sensor and transmitter are integrated into a single device. Once applied, the device remains attached to the skin for the duration of wear and automatically transmits glucose data to the dedicated mobile application, without requiring repeated sensor scans or manual interaction.
However, initiation of monitoring requires an initial activation step through the Dexcom ONE+ mobile application. During this process, the user must create an account in the application, scan the QR code printed on the applicator or packaging, and bring the smartphone close to the sensor to complete device pairing. After activation, the system enters a warm-up period that allows sensor stabilization within the interstitial environment. Once this period is complete, glucose values are transmitted automatically and continuously, without further user intervention.
Foreigner In Romania and in need of a prescription for your chronic treatment?
Contact Dr. Petrache’s Virtual Clinic for any medical issue you encounter while in Romania. Send an email to: [email protected]
How Dexcom ONE+ Measures Glucose and How This Should Be Interpreted
Dexcom ONE+ does not measure capillary blood glucose. Instead, it measures glucose in the interstitial fluid. This distinction is essential to understand in order to avoid common misunderstandings when comparing CGM values with finger-stick measurements.
Glucose reaches the interstitial space with a slight delay compared to the bloodstream. Under stable conditions, this delay is minimal and clinically insignificant. During periods of rapid glucose change—such as after carbohydrate-rich meals, during physical activity, or in hypoglycemia—the difference may become more noticeable. This phenomenon is physiological and does not represent sensor inaccuracy.
For this reason, Dexcom ONE+ should be understood primarily as a tool for identifying trends and patterns rather than focusing exclusively on single numerical values. The direction and speed of glucose change often provide more meaningful information than a point value alone.
What the Dexcom ONE+ Application Displays
The Dexcom ONE+ mobile application is intentionally designed to be clear and easy to use. It displays the current glucose value, the glucose curve over time, and trend arrows indicating the direction of glucose change. This allows users to observe how their glucose responds to meals, physical activity, sleep, and stress without the need for repeated finger-stick testing.
Alerts for low or high glucose values are also available within the limits of the system’s configuration. These alerts are informational and support awareness of glycemic fluctuations rather than automatic decision-making.
What Dexcom ONE+ Does Not Do
Understanding the limitations of Dexcom ONE+ is as important as understanding its capabilities. The system does not establish diagnoses, does not recommend treatments, and does not calculate insulin doses. It also does not interpret the causes of glucose changes. It shows what is happening, not why it is happening.
In certain situations, confirmation with a glucometer remains necessary, particularly when symptoms do not match displayed values or during periods of rapid glucose change. This does not reduce the value of CGM, but reflects correct and responsible use.
Passing through Romania and need a prescription for your chronic treatment?
Contact Dr. Petrache’s Virtual Clinic for any medical issue you encounter while in Romania. Send an email to: [email protected]
The Role of Dexcom ONE+ in Romania
In the Romanian context, Dexcom ONE+ serves a clear purpose: it is an accessible continuous glucose monitoring tool suitable for metabolic education, prevention, and understanding daily glycemic variability. It enables users to observe their own glucose patterns and make informed lifestyle adjustments without the complexity of a fully integrated technological ecosystem.
Dexcom ONE+ is not an inferior version of the G7. It is an adapted version that preserves the technological core of the Dexcom platform while aligning with the realities of the local healthcare environment.
Dexcom G7: What It Adds and Why It Matters Only in Certain Contexts
Dexcom G7 represents the full-featured version of the Dexcom continuous glucose monitoring platform, designed for healthcare environments where CGM is already deeply integrated into routine clinical practice. From a measurement standpoint, Dexcom G7 operates on the same physiological principles as Dexcom ONE+. It measures glucose in the interstitial fluid and provides continuous data on glycemic evolution. The difference lies not in what is measured, but in how the information can be used within a broader technological ecosystem.
In daily use, Dexcom G7 is intended to function as part of a more complex system. The application provides the same core elements—current glucose values, trend arrows, and glucose curves—but it also supports additional software features that enable more advanced use of CGM data. These include more sophisticated alert configurations and, in certain regions, predictive alerts designed to warn of impending hypoglycemia before it occurs.
The defining characteristic of Dexcom G7 is its ability to integrate seamlessly with other medical technologies. In countries where it is widely available, G7 is often connected to insulin pumps or automated insulin delivery systems. In such settings, CGM data are not only observed by the user, but also used by algorithms that adjust insulin delivery in real time. For this type of use, system reliability, data continuity, and compatibility with external devices are critical, and Dexcom G7 is optimized to meet these requirements.
In Romania, this type of integrated ecosystem is still limited. The number of insulin pump users is relatively small, and standardized CGM–pump integration is not yet broadly accessible. Without this infrastructure, many of the advanced features of Dexcom G7 would remain underutilized. As a result, the practical difference between Dexcom G7 and Dexcom ONE+ would be minimal for most users in the local context.
It is also important to clarify what “more advanced” means in this setting. Dexcom G7 is not more advanced because it measures glucose more accurately in everyday use. Instead, it is more advanced because it is designed to operate within a system that supports automation, predictive alerts, and integrated decision support. When that system is absent, the additional complexity does not necessarily translate into meaningful clinical benefit.
For this reason, the absence of Dexcom G7 from the Romanian market does not represent a true disadvantage for the majority of users. Dexcom ONE+ already provides the essential information needed for metabolic education, prevention, and understanding daily glycemic variability. Dexcom G7 becomes relevant primarily in contexts where CGM data are part of a larger, interconnected technological framework.
Final Conclusion: How Dexcom’s Strategy Should Be Understood and the Role of Dexcom ONE+ in Romania
The difference between Dexcom ONE+ and Dexcom G7 is often misinterpreted as a difference in measurement quality or technological level. In reality, this is not a distinction between “better” and “worse” devices, nor between older and newer generations. Instead, it reflects two configurations of the same technological platform, adapted to different healthcare environments and levels of system maturity.
Dexcom’s strategy should not be viewed as discriminatory toward the Romanian market. On the contrary, it represents a pragmatic approach that takes into account how technology can be used effectively and sustainably in a given context. A continuous glucose monitoring system does not exist in isolation. Its real value emerges only when it is integrated into a healthcare framework that can support its level of complexity.
In Romania, limited reimbursement options, reduced access to insulin pump therapy, and a still-developing infrastructure for advanced diabetes technology mean that a highly integrated CGM system would not be used to its full potential. In such circumstances, introducing a fully featured platform would increase costs and complexity without delivering proportional clinical benefit for most users.
Tourist in Romania and in need of a prescription for your chronic treatment?
Contact Dr. Petrache’s Virtual Clinic for any medical issue you encounter while in Romania. Send an email to: [email protected]
Dexcom ONE+ addresses this reality by providing true continuous glucose monitoring with clear visualization of values, trends, and essential alerts. It offers the core information required to understand glycemic variability, support metabolic education, and encourage informed lifestyle adjustments. For the majority of users, these elements represent the most meaningful and actionable aspects of CGM.
Dexcom ONE+ should therefore be seen as a natural step in the maturation of the CGM market. It allows users and healthcare professionals to become familiar with continuous glucose data, to develop confidence in trend-based interpretation, and to build a culture of data-informed metabolic care. As healthcare systems evolve, reimbursement expands, and integration with other technologies becomes more widespread, progression toward more complex systems becomes both logical and feasible.
From a medical and educational perspective, the correct message is clear: Dexcom ONE+ delivers the essential information that most users currently need. Dexcom G7 becomes relevant in specific contexts where continuous glucose data are part of a broader, interconnected technological ecosystem. The difference between the two is not a matter of quality, but of purpose and level of integration.
Follow us on:
- FaceBook: Diabetes & Nutrition;
- YouTube: Diabetes Facts.
